Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Intellinetics Q4 2025 Earnings Call - SaaS growth cushions services slump, investments weigh on profitability
Intellinetics closed 2025 with clear progress in SaaS, but not yet with a clean bill of health. SaaS revenue grew double digits for the year and was up 8.4% in Q4, improving margins and offsetting a m...
- CEO change: Alison Forsythe became CEO in mid-February and focused immediately on operations, go-to-market, and execution improvements.
- Q4 revenue: Total revenue for Q4 2025 was $4.3 million, up 1% year over year.
- SaaS growth: SaaS and hosting revenue rose 8.4% year over year in Q4 to $1.6 million; SaaS grew 11.1% for the full year.
- +11 more takeaways
Fermi America Q4 & FY 2025 Earnings Call - Matador substantially built, now hostage to tenant leases and project financing
Fermi America is no longer a paper promise, it is a construction site. Management reports roughly $570 million deployed into Project Matador, $935 million of PP&E in construction in progress, and key ...
- Project Matador has moved from formation to heavy construction: ~$570 million of investor capital deployed into Matador (construction in progress), PP&E of ~$935 million as of 12/31/2025.
- Company is pre-revenue. Net loss for the fiscal period was $486 million, with ~$445 million non-cash items; operating cash use was $34 million for the year.
- Cash and liquidity: $409 million cash on 12/31/2025, plus ~ $1 billion of financing proceeds in 2025 and subsequent equipment facilities (MUFG $500m turbine warehouse, Keystone $120m expandable, Yellowstone $165m) that, with cash, provide at least 12 months of liquidity.
- +11 more takeaways
PAVmed Fourth Quarter 2025 Earnings Call - Capital Structure Cleaned, Lucid Momentum and Medtech Relaunch Set the Agenda
PAVmed says the long, painful chapter of toxic convertibles is over. A February recapitalization and financing left the company with a clean cap table, roughly $30 million of new equity, $15 million o...
- Recapitalization completed in February removed legacy toxic convertible securities and produced a clean cap table, converting $30 million of short-term preferred into common and adding $15 million of 3-year, 15% interest-only debt.
- PAVmed now shows pro forma total assets north of $100 million after the financing, with $15 million of long-term debt on the balance sheet and a $30 million warrant package tied to the Series D.
- PAVmed remains the single largest shareholder of Lucid Diagnostics, holding roughly 31 million shares (equity method investment approx. $34 million) and about an 18% ownership stake, with ~25% voting interest.
- +16 more takeaways
Bicara Therapeutics Q4 2025 Earnings Call - Breakthrough Therapy Designation and 1,500 mg Weekly Chosen as Pivotal Dose with Mid-2027 Interim for Accelerated Approval
Bicara used its first quarterly call to tighten the story: ficerafusp alfa is now positioned as a potential best-in-class, chemo-sparing therapy for frontline recurrent/metastatic HPV-negative head an...
- FDA granted Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab for first-line metastatic or unresectable HPV-negative head and neck squamous cell carcinoma.
- Company selected 1,500 mg weekly as the optimal biological dose and has advanced FORTIFY-HN01 into the phase III portion with 2-to-1 randomization versus pembrolizumab monotherapy.
- Planned interim analysis for FORTIFY-HN01 is expected mid-2027, focused on overall response rate, durability of response and qualitative overall survival, reviewed by an IDMC while management remains blinded.
- +12 more takeaways
Rezolve AI 2H & FY2025 Earnings Call - Exit ARR $232.8M, Upgraded 2026 Revenue Guidance to $360M
Rezolve AI says 2025 was the inflection year. The company exited December with $19.4 million in MRR, implying a $232.8 million ARR, reported $46.8 million in full-year revenue, and claims the second h...
- Exit December MRR was $19.4 million, implying an exit ARR of $232.8 million (audited figure disclosed in the 20-F).
- Full-year 2025 GAAP revenue was $46.8 million, with a 543% acceleration in the second half as customers moved into production.
- Management upgraded 2026 GAAP revenue guidance to $360 million, and is targeting a $500 million ARR at year-end 2026.
- +12 more takeaways
Nano Labs Ltd Second Half 2025 Earnings Call - BNB reserves and crypto income drive profit while cash and inventory hits raise questions
Nano Labs frames H2 2025 as a strategic inflection: it built a large BNB reserve, booked hefty crypto-related other income, and pivoted toward AI agent hardware with the March 2026 launch of the iPoll...
- As of December 31, 2025 the company reported holding 126,662 BNB and 3,338 BNB as receivable collateral, naming BNB a core element of its strategic crypto reserve.
- Management completed two financing rounds in 2025 to support strategic transformation, expanded crypto reserves, and new business directions.
- Company announced a share repurchase program in October 2025 of up to $25 million, and has begun implementing it gradually.
- +12 more takeaways
Sigma Lithium Q4 2025 Earnings Call - Cash machine as dry-stack fines fund debt paydown, Plant Two set for early 2027 commissioning
Sigma spent 2025 turning operational pain into cash. Management monetized dry-stack tailings by reprocessing lithium fines, generating meaningful cash sales that funded a sizable debt paydown and kept...
- New revenue line, reprocessing dry-stack tailings into high-purity lithium fines, materially boosted cash flow; Q1 2026 fines sales included roughly $30 million.
- Sigma signed about $146 million of offtake prepayments in 2025: $96 million for 70,000 t (2026 deliveries) and a $50 million 3-year typical offtake for 40,000 t/year (120,000 t total).
- Management repaid roughly 60% of short-term debt and about 35% of total debt year over year, without raising new equity.
- +12 more takeaways
Neumora Therapeutics Q4 2025 Earnings Call - Catalyst-rich pipeline: navacaprant readouts in Q2 2026, NMRA-215 delayed to Q1 2027 after rat tox audit
Neumora positions itself for a busy 12 months, with two phase III readouts for navacaprant expected in Q2 2026, multiple phase I/II data points across M4 PAMs and NMRA-511 through 2026, and a planned ...
- Neumora expects multiple near-term clinical catalysts: KOASTAL-2/KOASTAL-3 top-line in Q2 2026, NMRA-511 MAD extension readout H2 2026, NMRA-898 MAD data H2 2026, and NMRA-511 phase II initiation in Q1 2027.
- KOASTAL-2 and KOASTAL-3 (navacaprant, KOR antagonist for MDD) are fully enrolled with >400 patients each; a joint top-line readout will include individual study results plus pre-specified post-pause pooled analyses.
- Following protocol optimizations after KOASTAL-1, Neumora implemented SAFER procedures, enhanced screening to exclude professional patients, and pared sites; screen-fail rates rose ~10% versus KOASTAL-1, which management views as higher quality enrollment.
- +12 more takeaways
CBAK Energy Technology Q4 2025 and FY2025 Earnings Call - 40135/32140 Capacity Ramp Sparks Revenue Surge but Squeezes Margins
CBAK spent 2025 reshaping its product mix and capacity footprint, and the results are mixed, fast and messy. Management is racing new 40135 and 32140 production lines into service to meet demand that ...
- Q4 consolidated net revenue reported at $58.80 million, up 131.8% year over year.
- Management provided conflicting full-year top-line figures on the call, with the CEO stating consolidated net revenue of $100.19 million while the CFO reported $195.19 million; the discrepancy also appears in Hitrans figures.
- Hitrans raw-materials segment reported a sharp rebound, management saying it surged 123% year over year; CEO cited $89.21 million for Hitrans while the CFO cited $188.92 million, underscoring the reporting inconsistency that requires clarification.
- +16 more takeaways
PubMatic Q4 2025 Earnings Call - Agentic AI adoption accelerates, setting up H2 2026 double-digit growth
PubMatic reported a strong Q4 that beat guidance on revenue and adjusted EBITDA, with Q4 adjusted EBITDA of $27.8 million, a 35% margin, and free cash flow up 32% year over year. The quarter was drive...
- Q4 beat: revenue and adjusted EBITDA exceeded guidance, with Q4 adjusted EBITDA of $27.8 million, representing a 35% margin.
- Agentic AI is front and center: PubMatic says agentic advertising is an incremental tailwind, and the company has already run over 250 agentic deals.
- Early agentic performance claims include a pilot delivering more than 5x cost efficiencies, 87% faster campaign setup, and 70% faster issue resolution.
- +11 more takeaways